All In Biotech

Drug Trial Radar · NCT07013474

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jul 14, 2025

Primary completion

Sep 28, 2027

Study completion Feb 5, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized at baseline with mild-to-moderate COVID-19.

Conditions

  • COVID-19 Infection

Interventions

  • ibuzatrelvirDrug

    tablet

  • remdesivirDrug

    injection, for intravenous use

  • placebo for ibuzatrelvirDrug

    tablet

  • placebo for remdesivirDrug

    injection, for intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The difference in the proportion of patients meeting the primary composite endpoint, between ibuzatrelvir and remdesivir vs remdesivir groups in symptomatic adult participants with COVID-19 who are severely immunocompromisedTime frame: 38 days

Locations

159 sites in 18 countries. Site status is shown where the registry gives one.

  • Hope Clinical Research, Inc.

    Canoga Park, California · Recruiting

  • Amicis Research Center - Granada Hills

    Granada Hills, California · Recruiting

  • Jacobs Medical Center at UC San Diego Health

    La Jolla, California · Recruiting

  • UC Davis CTSC Clinical Research Center

    Sacramento, California · Recruiting

  • University of California Davis Health

    Sacramento, California · Recruiting

  • UC San Diego Medical Center - Hillcrest

    San Diego, California · Recruiting

  • University of California San Diego Health

    San Diego, California · Recruiting

  • UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • University of Colorado Clinical and Translational Research Center

    Aurora, Colorado · Recruiting

  • University of Colorado Hospital

    Aurora, Colorado · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • BRP- Hialeah Hospital

    Hialeah, Florida · Recruiting

  • D&H Cancer Research Center LLC

    Margate, Florida · Recruiting

  • Kendall South Medical Center

    Miami, Florida · Recruiting

  • Velocity Clinical Research, Savannah

    Savannah, Georgia · Recruiting

  • Humphreys Diabetes Center

    Boise, Idaho · Recruiting

  • St. Luke's Idaho Elks Children's Pavilion

    Boise, Idaho · Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinois · Recruiting

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Jadestone Clinical Research

    Silver Spring, Maryland · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Clinical Trials Center

    Boston, Massachusetts · Recruiting

  • Clinical Trials Hub

    Boston, Massachusetts · Recruiting

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Hospital

    Detroit, Michigan · Recruiting

  • Holy Name Medical Center

    Teaneck, New Jersey · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Duke Vaccine and Trials Unit

    Durham, North Carolina · Recruiting

  • Duke Vaccine and Trials Unit

    Durham, North Carolina · Recruiting

  • Duke University - Main Hospital and Clinics

    Durham, North Carolina · Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • University of Cincinnati College of Medicine (UC Holmes)

    Cincinnati, Ohio · Recruiting

  • TRC

    Pittsburgh, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • UPMC Division of Infectious Disease Clinic

    Pittsburgh, Pennsylvania · Recruiting

  • UPMC Presbyterian IDS

    Pittsburgh, Pennsylvania · Recruiting

  • UPMC Presbyterian Shadyside

    Pittsburgh, Pennsylvania · Recruiting

Showing 40 of 159 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.